Omega-3 Fatty Acids Are More Beneficial in the Depressive Phase Than in the Manic Phase in Patients With Bipolar I Disorder

Article AbstractBecause this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.Sir: An intramuscular (IM) formulation of olanzapine wasapproved by the U.S. Food and Drug Administration (FDA) inMarch 2004 for the treatment of agitation associated withschizophrenia and bipolar I disorder.1 The package insert for IMolanzapine reports significant incidence of orthostatic hypotensionin one third of nonagitated patients with schizophrenia whowere treated with the maximum recommended dosage of olanzapineIM (three 10-mg doses administered 4 hours apart).1Forty-nine adverse events, 29 of which were deemed seriousand 8, fatal, were reported in Europe.2†‹